Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Pfizer Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Pfizer Ltd has informed BSE regarding the details of Voting results at the 65th Annual General Meeting (AGM) of the Company held on July 05, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Outcome of AGM
Pfizer Ltd has informed BSE that the 65th Annual General Meeting (AGM) of the Company was held on July 05, 2016. Pfizer to invest $350 million in China biotech hub, first in Asia
The facility in eastern Hangzhou region - Pfizer's first biotech centre in Asia - is expected to be completed by 2018. Pharma biggies like Cipla, Pfizer among 200 under lens for poor drugs
According to a source, notices have been issued recently to Cipla and Pfizer informing them of the upcoming inspection as well as violations found in their products. Intimation of Schedule of Analyst / Institutional Investor Meetings
Pfizer Ltd has informed BSE regarding "Intimation of Schedule of Analyst / Institutional Investor Meetings". Fixes Book Closure for Dividend & AGM (Cut-off date for e-voting)
Pfizer Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from June 29, 2016 to July 05, 2016 (both days inclusive) for the purpose of Payment of Dividend & Annual General Meeting (AGM) of the Company to be held on July 05, 2016. Intimation of Schedule of Analyst / Institutional Investor Meetings
Pfizer Ltd has informed BSE regarding "Intimation of Schedule of Analyst / Institutional Investor Meetings". Intimation of Schedule of Analyst / Institutional Investor Meetings
Pfizer Ltd has informed BSE regarding "Intimation of Schedule of Analyst / Institutional Investor Meetings".
Novartis breast cancer drug set to take on Pfizer's Ibrance, assuming 2018 launch
The lab testing was stopped early because of its good results, plans to divide the pharmaceutical division in two unit,one focusing only on cancer drugs.